volagidemab: Clinical Trials

6 trials of volagidemab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 active not recruiting. 6 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Active not recruiting 2
Phase 14Completed 3, Active not recruiting 1

Follow volagidemab: new trials by email Literature Review of volagidemab trials Research Report on volagidemab

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
Sotagliflozin, Volagidemab - Type 1 Diabetes
Phase 1 / Phase 2Active not recruitingUniversity of California, San Diego242024-09-092026-06-15
Effects of GRA in Patients With Type 1
REMD-477, Placebo - Type 1 Diabetes
Phase 2Active not recruitingUniversity of California, San Diego302021-07-312025-06-10
Combination GRA and SGLT-2i Treatment in Type 1 Diabetes
Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo - Type 1 Diabetes
Phase 1 / Phase 2CompletedUniversity of California, San Diego122021-02-222023-01-23
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
REMD-477 - Type 1 Diabetes Mellitus
Phase 1 / Phase 2CompletedUniversity of California, San Diego42019-07-012022-07-15
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
REMD-477, Placebo Comparator - Type1 Diabetes Mellitus
Phase 2CompletedREMD Biotherapeutics, Inc.1542017-09-192023-05-25
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
REMD-477 - Type 2 Diabetes Mellitus, Diabetes
Phase 1 / Phase 2CompletedREMD Biotherapeutics, Inc.752015-09-012018-04-10

Conditions studied

Diabetes Mellitus, Type 1 (4)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)

Sponsors

University of California, San Diego (4)  ·  REMD Biotherapeutics, Inc. (2)

Countries

United States (6)

Results publications

PMID 39146397